PHVS 21.25 Pharvaris N.V.
| Range: | 15.0-33.0 | Vol Avg: | 90087 | Last Div: | 0 | Changes: | 1.9 |
| Beta: | -3.1 | Cap: | 1.07B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 05 2021 | Empoloyees: | 83 | ||
| CUSIP: | N69605108 | CIK: | 0001830487 | ISIN: | NL00150005Y4 | Country: | NL |
| CEO: | Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Website: | https://pharvaris.com | ||||
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Stock Details
Neutral 0.02
Pharvaris to Host Virtual Investor Event on October 23, 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage...
globenewswire.com·Tue Oct 15 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow